Bilgen Gençler

Dr. Bilgen Gençler


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2016 in Dermatology Research and Practice
Verified
Journal Article
Open access
PDF file
BGBilgen Gençler
Bilgen Gençler
MGMüzeyyen Gönül
Müzeyyen Gönül
The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.

15 March 2017
Verified
Book Chapter
Open access
PDF file
BGBilgen Gençler
Bilgen Gençler
OKOzge Keseroglu
Ozge Keseroglu
SKSelda Pelin Kartal
Selda Pelin Kartal
MGMuzeyyen Gonul
Muzeyyen Gonul
Pediatric Acne | InTechOpen, Published on: 2017-03-15. Authors: Bilgen Gencler, Ozge Keseroglu, Selda Pelin Kartal, et